Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • EGFR
    (1)
  • Others
    (9)
Filter
Search Result
Results for "

target/AChE/2

" in TargetMol Product Catalog
  • Inhibitor Products
    10
    TargetMol | Activity
Multi-target kinase inhibitor 2
T81739
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values between 40 to 204 nM. It exhibits cytotoxic effects on HepG2, HeLa, MDA-MB-231, and MCF-7 cell lines, with IC50 values of 41, 57, 51, and 59 μM, respectively. Additionally, it induces cell cycle arrest and apoptosis specifically in HepG2 cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AChE/BuChE/MAO-B-IN-2
T78679
AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent inhibitor of AChE, BuChE, and hu MAO-B, with respective IC50 values of 5.3 μM, 12.4 μM, and 1.9±0.08 μM, indicating good in vitro blood-brain barrier (BBB) permeability. It is effective in reducing excessive AChE and BuChE levels associated with Alzheimer's disease (AD) and holds potential for use in anti-Alzheimer's research [1].
  • Inquiry Price
Size
QTY
AChE/MAO-IN-2
T72893
Dual AChE-MAO B-IN-5, an indanone derivative, serves as an effective dual inhibitor for AChE and MAO-B, displaying IC50 values of 0.0224 μM for AChE, 0.0412 μM for MAO-B, and 0.1116 μM for MAO-A. Additionally, it exhibits antioxidant properties and inhibits β-amyloid plaque aggregation, making it suitable for Alzheimer’s disease (AD) research.
  • $1,520
6-8 weeks
Size
QTY
Dual AChE-MAO B-IN-2
T621521801157-64-1
Dual AChE-MAO B-IN-2 is a potent, dual inhibitor of AChE (IC50: 0.12 μM) and MAO B (IC50: 0.01 μM).Dual AChE-MAO B-IN-2 has potential for Alzheimer's disease studies.
  • $1,520
6-8 weeks
Size
QTY
AChE/BChE/BACE-1-IN-2
T606911877000-20-8
AChE/BChE/BACE-1-IN-2 (Compound 4o) exhibits remarkable antioxidant potential and considerable binding capability towards PAS-AChE. AChE/BChE/BACE-1-IN-2 is an orally active AChE, BACE-1 and BChE inhibitor with IC 50 values of 0.069, 0.097 and 0.127 μM against hAChE, hBACE-1 and hBChE, respectively. AChE/BChE/BACE-1-IN-2 shows potential disassembly of Aβ aggregates and neuroprotective activity against Aβ-induced stress with excellent brain permeation [1].
  • $1,520
6-8 weeks
Size
QTY
AChE/BChE-IN-2
T622742761991-42-6
AChE/BChE-IN-2 (Compound 13b) is a potent inhibitor of AChE/BChE with IC50 values of 0.96 ± 0.14 μM and 1.23 ± 0.23 μM for AChE and BChE, respectively.
  • $1,520
6-8 weeks
Size
QTY
AChE/Aβ-IN-2
T79571
AChE/Aβ-IN-2 (compound 33) is a powerful, orally active acetylcholinesterase (AChE) inhibitor with an IC50 of 135 nM. It also functions as an NMDA receptor antagonist (GluN1-1b/GluN2B subunit combination) with an IC50 of 5.054 μM, inhibits Aβ aggregation, and exhibits favorable blood-brain barrier permeability. Additionally, it enhances cognitive and spatial memory in a rat model [1].
  • Inquiry Price
Size
QTY
AChE/BChE/MAO-B-IN-2
T72452
AChE/BChE/MAO-B-IN-2 is a potent inhibitor of the enzymes AChE, BChE, and MAO-B, with IC50 values of 48.2 nM, 83.9 nM, and 31.2 nM, respectively. It exhibits significant antioxidant activity and is applicable in Parkinson’s disease research.
  • $1,520
6-8 weeks
Size
QTY
AChE/BuChE-IN-2
T608371946008-31-6
AChE/BuChE-IN-2 (Compound 5f) can cross the BBB that is an orally active inhibitor of AChE and BuChE with IC 50 values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows potent inhibition of self-induced β-amyloid (Aβ) aggregation with an IC 50 of 62.52 μM and a non-competitive inhibition with AChE [1].
  • $1,520
6-8 weeks
Size
QTY
sEH/AChE-IN-2
T728742490589-09-6
sEH/AChE-IN-2 and acetylcholinesterase ( AChE ). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .
  • $1,520
6-8 weeks
Size
QTY